HSD11β1 promotes EMT-mediated breast cancer metastasis

Joji Nakayama^{1, 2, §}, Takamasa Ishikawa^{3, 4}, Tatsunori Nishimura⁵, Sanae Yamanaka³, Noriko Gotoh⁵, Chisako Yamauchi⁶, Tatsuya Ohnishi⁶, Tomoyoshi Soga⁴, Satoshi Fujii^{6, 8} and Hideki Makinoshima^{1, 2, 9}

¹Tsuruoka Metabolomics Laboratory, National Cancer Center, Tsuruoka, Japan

²Shonai Regional Industry Promotion Center, Tsuruoka, Japan

³Infinity lab, Tsuruoka, Japan

⁴Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan

⁵Division of Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

⁶Department of Breast Surgery, Hospital east, National Cancer Center

⁷Department of Molecular Pathology, Yokohama City University School of Medicine

⁸Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, East

⁹Division of Translational Genomics, Exploratory Oncology Research and Clinical Trials Center, National Cancer Center

§Corresponding author: Joji Nakayama

Tsuruoka Metabolomics Laboratory, National Cancer Center

246-2, Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan 997-0052

E-mail: zmetastasis@gmail.com

Total words excluding online methods, references, and figure legends: 2563

Total figures: 4

Total extended data: 10

Abstract

Abnormal biosyntheses of steroid hormones and dysregulation of steroid hormone receptors contribute to breast cancer metastasis but the mechanisms of that are poorly understand. Here we report a stress hormone producing enzyme, Hydroxysteroid (11-Beta) Dehydrogenase 1 (HSD11 β 1) promotes breast cancer metastasis. HSD11 β 1 was ectopically expressed in seventy-one percent of triple-negative breast tumors and correlated with shorter overall survival. HSD11 β 1 significantly promoted breast cancer metastasis through induction of epithelial-to-mesenchymal transition (EMT); conversely, pharmacologic and genetic inhibition of HSD11 β 1 suppressed metastatic progression of breast cancer cells. Moreover, 11-hydroxyprogesterone (11-OHP) whom HSD11 β 1 produced in breast cancer cells, conferred metastatic properties on non-metastatic breast cancer cells through induction of EMT. We identified Peroxisome Proliferator-activated Receptor Alpha (PPAR- α) as essential for both HSD11 β 1 and 11OHP-driven EMT. Knockdown of PPAR- α induced MET on HSD11 β 1-expressing breast cancer cells. Taken together, HSD11 β 1 promotes breast cancer metastasis and would be a novel target for suppressing breast cancer metastasis.

Main text

Metastasis is responsible for approximately 90% of cancer-associated mortality and proceeds through multiple steps¹⁻³. EMT and its reverse process, mesenchymal-to-epithelial transition (MET) contribute to the steps⁴⁻⁶. In mammary tumor, multiple subpopulations of breast cancer cells exist and show different EMT stages; either epithelial, mesenchymal or intermediate hybrid state^{7,8}. Multiple signaling pathways and transcription factor networks govern EMT but the mechanisms of that are still largely unknown.

Abnormal biosyntheses of steroid hormones and oxysterols and dysregulation of steroid hormone receptors contribute to breast cancer metastasis⁹⁻¹². HSD11 β 1 is a bi-directional enzyme catalyzing both oxo-reductase and dehydrogenase reactions normally expressed in key metabolic tissues: the adrenal cortex, liver, adipose tissue, and the central nervous system¹³. HSD11 β 1 has broad substrate specificity and the metabolites whom HSD11 β 1 produces are related with malignancy of cancer cells¹⁴⁻¹⁶. Previous study demonstrated inhibiting HSD11 β 1 suppress metastatic dissemination of cancer cells, but the mechanisms of how HSD11 β 1 promotes metastasis remains to be elucidated¹⁷.

HSD11 β 1 expression correlates with poor prognosis of breast cancer patients

We first examined HSD11 β 1 expression in fourteen human breast cancer cell lines with different metastatic properties. Western blotting analyses revealed that HSD11 β 1 protein was detected only in breast cancer cells with mesenchymal traits and not those with epithelial traits (Fig. 1a). The expression levels of HSD11 β 1 mRNA did not correlate with those of HSD11 β 1 protein (Extended Data Fig. 1a). Immunohistochemistry (IHC) staining on tissue microarrays containing 242 breast cancer cases, revealed that 71% (n=27/38) of triple-negative and 75% (n=12/16) of HER2-positive breast tumors showed HSD11 β 1 expression; while only 42.6% (n=60/141) of luminal A and 53.2% (n=25/47) of luminal B breast tumors

showed expression. In accordance with an inverse correlation between HSD11 β 1 expression and epithelial traits in the cell lines, the clinical samples showed an inverse correlation between HSD11 β 1 and E-cadherin expression (Fig. 1b, c and Extended Data Fig. 1b).

We determined the prognostic significance of HSD11 β 1 by assessing the 242 cases with known clinical follow-up data. Kaplan–Meier survival analysis revealed a correlation between HSD11 β 1 expression and shorter overall survival time among the 242 cases ($p=0.0889$). In each subtype, HSD11 β 1-positive patients with triple-negative, HER2-positive, and luminal B showed shorter overall survival time compared with HSD11 β 1-negative patients. Conversely, there is no correlation of HSD11 β 1 expression with shorter overall survival in the luminal A subtype ($p=0.2576$) (Fig. 1d). These results suggest that HSD11 β 1 might be involved in breast cancer metastasis, especially loss of epithelial traits.

HSD11 β 1 promotes EMT-mediated breast cancer metastasis

Loss of E-cadherin expression is the most predominant hallmark of EMT⁴⁻⁶. We therefore elucidated whether HSD11 β 1 might contribute to the induction of EMT. Elevated expressions of HSD11 β 1 was detected in MCF10A and HuMEC human mammary cells when these cells underwent EMT. Surprisingly, only HSD11 β 1 expression was sufficient to induce EMT in these cells (Fig. 2a and Extended Data Fig 2a and b). Sub-clones of human MCF7 breast cancer cells which expressed HSD11 β 1 (#2-7 and #2-19) also showed EMT hallmarks: a spindle-like, fibroblastic morphology; complete loss of E-cadherin and EpCAM; and abundant expression of N-cadherin and vimentin. In contrast, a sub-clone of MCF7 cells which expressed a catalytic mutant of HSD11 β 1 (K181N/Y183F) failed to induce EMT (Fig. 2a and b). Furthermore, Boyden chamber assays demonstrated that MCF7-HSD11 β 1 sub-clones #2-7 and #2-19 showed approximately a 30-fold increase of cell motility and invasion compared to control clones that were transduced with either empty vector (VC) or HSD11 β 1

K181N/Y183F (Fig. 2c). These results indicate that HSD11 β 1 expression is sufficient to induce EMT and its catalytic activity plays an essential role in that process.

We next examined whether ectopic expression of HSD11 β 1 was sufficient to confer metastatic properties on non-metastatic MCF7 cells. A sub-clone of either VC or #2-19, both of which expressed luciferase, were injected into the mammary fat pad (MFP) of NOD-*scid*-*Il2rg^{null}* (NSG) immunodeficient mice. At three weeks post-inoculation, primary tumors of #2-19 cells grew larger than that of VC cells. Western blot analyses showed ki-67 levels in the tumors of #2-19 cells were increased compared with VC cell tumors (Extended Data Fig. 2c and d). At four weeks post-inoculation, these tumors were removed from the mice, and metastasis progression was monitored by bioluminescence imaging of the mice. Surprisingly, at six weeks post-inoculation, the mice inoculated with #2-19 cells, showed metastatic tumor burden in the lungs, liver, spleen and lymph-nodes. In contrast, the mice inoculated with VC cells did not show any metastatic tumors in these organs (Fig. 2d and e and Extended Data Fig. 3a). Histologic analyses confirmed that metastatic lesions in the lungs were detected in all of the mice inoculated with #2-19 cells; conversely, none were detected in of the mice inoculated with VC cells (Extended Data Fig. 3b). These results indicate that HSD11 β 1 expression is sufficient to induce EMT and confers metastatic properties on non-metastatic MCF7 cells.

Pharmacological and genetic inhibition of HSD11 β 1 suppressed breast cancer metastasis

We conducted an inverse examination of whether HSD11 β 1 might be essential for breast cancer metastasis. A sub-clone of MDA-MB-231 cells expressing shRNA targeting either LacZ or HSD11 β 1, both of which expressed luciferase, were injected into the MFP of NSG mice. At four weeks post-inoculation, primary tumors were removed and marker expression

of the removed tumors was investigated. Western blot analysis showed HSD11 β 1 knockdown in MDA-MB-231 cells (shHSD11 β 1_231) induced re-expression of E-cadherin. Other breast cancer cell lines, SUM-159PT and Hs578T cells, also re-express E-cadherin when HSD11 β 1 expression was silenced in these cells through RNA interference (Fig. 3a and Extended Data Fig. 4a). Ten weeks after removal of the primary tumors, bioluminescent imaging demonstrated that the mice inoculated with shLacZ_231 cells showed metastatic burden in the lungs and liver; conversely, most of the mice inoculated with shHSD11 β 1_231 cells (all but three mice) did not show any metastatic tumor in these organs (Fig. 3b and Extended Data Fig. 4b). The mice inoculated with shLacZ_231 cells formed 10 to 600 metastatic nodules per lung in all 7 mice analyzed; conversely, the mice inoculated with shHSD11 β 1_231 cells formed 0 to 200 nodules per lung in all 14 mice analyzed (Fig. 3c). Histologic analyses confirmed that metastatic lesions in the lung were detected in all of the mice inoculated with shLacZ_231 cells; conversely, they were detected in only 3 of 14 of the mice inoculated with shHSD11 β 1_231 cells and the rest of the mice showed metastatic formations around the bronchiole of the lung (Extended Data Fig. 4c). In the primary tumors of the 3 mice which inoculated with shHSD11 β 1_231 cells and showed metastasis, HSD11 β 1 expression was recovered (Extended Data Fig. 4d). These results indicate HSD11 β 1 would be a novel target for blocking breast cancer metastasis.

We further examined whether pharmacological inhibition of HSD11 β 1 might suppress breast cancer metastasis. Two days before cancer cell inoculation, the mice were randomly assigned to two groups and one group were inoculated with a pellet that continuously releases Adrenosterone, a competitive inhibitor for HSD11 β 1 while the other group received a vehicle injection. At three weeks post-inoculation, primary tumors of Adrenosterone-treated mice were smaller than that of vehicle-treated mice. At four weeks post-inoculation, primary tumors were removed and then proliferation and apoptosis markers

were investigated in the tumors. Western blot analyses showed ki-67 levels in the tumors of Adrenosterone-treated mice were decreased compared with those of vehicle-treated mice. (Extended Data Fig. 5a-c). Eight weeks after inoculation, bioluminescent imaging detected light emitted in the lungs, livers and lymph nodes of vehicle-treated mice but not those of Adrenosterone-treated mice (Fig. 3d). Vehicle-treated mice formed 512 to 1980 metastatic nodules per lung in all 10 mice analyzed; conversely, Adrenosterone-treated mice (n=12) formed 19 to 580 nodules per lung in all 10 mice analyzed. The number of metastatic nodules in the livers of Adrenosterone-treated mice significantly decreased compared with those of vehicle-treated mice (Fig. 3e). These results indicate that pharmacological and genetic inhibition of HSD11 β 1 suppressed breast cancer metastasis.

HSD11 β 1 produced 11 β -hydroxyprogesterone induced EMT.

Finally, we elucidated how HSD11 β 1 promoted EMT. Cortisol is one metabolite of HSD11 β 1 and is a glucocorticoids, a family of steroid hormones which are reported to promote breast cancer metastasis¹¹. We elucidated the involvement of cortisol in HSD11 β 1-driven EMT, however, ELISA and mass spectrometer analyses did not detect cortisol in HSD11 β 1-expressing breast cancer cell lines. Furthermore, cortisol treatment did not induce EMT of MCF10A and HuMEC cells. Moreover, half of HSD11 β 1-expressing breast cancer cell lines failed to convert cortisone into cortisol. (Extended Data Fig. 6a-c). We therefore conclude cortisol was not involved in HSD11 β 1-driven EMT.

HSD11 β 1 has broad substrate specificity¹³. Adrenosterone (11-keto androstenedione, 11KA4) which is an 11-oxygenated C19 steroid functions as a competitive selective HSD11 β 1 inhibitor^{18 17}. HSD11 β 1-expressing breast cancer cells converted Adrenosterone into 11-hydroxy androstenedione (11OHA4) (Extended Data Fig. 7a). Furthermore, HSD11 β 1-expressing breast cancer cells catalyzed 11-keto testosterone (11-KT) which is

also an 11-oxygenated C19 steroid known as a substrate for HSD11 β 1 into 11 β -hydroxy testosterone (11-OHT) ¹⁸. Also, Adrenosterone interrupted 11-OHT production (Extended Data Fig. 7b). Moreover, HSD11 β 1-expressing breast cancer cells showed elevated expression of the enzymes involved in production of 11-oxygenated C19 steroids (Extended Data Fig. 7c). Aberrant production of 11-oxygenated C19 steroids and alterations of the enzymes are reported to contribute to malignant progression in cancer cells ¹⁹⁻²¹. Therefore, we hypothesized that HSD11 β 1 might catalyze 11-oxygenated C19 steroids as a substrate and yield 11-hydroxy C19 steroids which induce EMT, and that Adrenosterone might function as a metastasis suppressor through interrupting the catalytic reaction. Mass spectrometer analyses demonstrated that HSD11 β 1-expressing breast cancer cells converted 11-keto progesterone (11-KP) and 11-keto-17 α -hydroxyprogesterone (21-Deoxycortisone) into 11 β -hydroxyprogesterone (11-OHP) and 11 β ,17 α -Dihydroxyprogesterone (21-DF), respectively. Also, Adrenosterone inhibited the production of these metabolites (Fig. 4a and Extended Data. Fig. 8a and b). We further demonstrated that 11-OHP-treated MCF10A cells underwent EMT and showed approximately two-fold increased invasion and migration compared with vehicle-treated the cells (Fig. 4b and c). Either 21-DF or 11-OHT-treated MCF10A cells showed similar effects (Extended Data Fig. 9a, b). Moreover, a zebrafish xenotransplantation model showed that 11-OHP-treated MCF7 cells increased metastatic dissemination compared with vehicle-treated controls (Fig. 4d). These results indicate that HSD11 β 1 produces 11-OHP which promotes metastatic dissemination of non-metastatic breast cancer cells through induction of EMT.

We further elucidated how 11-OHP induced EMT. C19 steroids are known to function as mediators through binding to nuclear receptors ²⁰. Therefore, we speculated that 11-OHP might bind to a nuclear receptor and induce EMT through up-regulation of EMT-inducible transcriptional factors. Genetic screening assays using siRNA libraries which

targeted 47 nuclear receptors revealed that knockdown of PPAR- α interrupted HSD11 β 1-driven EMT on MCF10A cells (Extended Data Fig. 9c). Furthermore, a sub-clone of HSD11 β 1-overexpressing MCF7 cells underwent MET when PPAR- α expression in the cells was silenced (Fig. 4e). In contrast, knockdown of glucocorticoid receptor (GR) which is a receptor for cortisol, did not induce MET in these cells (Extended Data Fig. 9d). Moreover, 11-OHP treatment did not induce EMT on a sub-clone of MCF10A cells which expressed shRNA targeting PPAR- α (Fig. 4f and g). Taken, together, these data suggested that HSD11 β 1-driven EMT and metastasis are mediated through PPAR- α .

Discussion

We present a new model of breast cancer metastasis, in which HSD11 β 1 becomes expressed during malignancy markedly promoting metastasis via EMT. Our data clearly demonstrates that approximately 70% of triple-negative and HER2-positive breast tumors express HSD11 β 1, and that HSD11 β 1 confers metastatic properties on non-metastatic breast cancer cells through induction of EMT. Moreover, we validated that pharmacologic and genetic inhibition of HSD11 β 1 suppressed metastatic progression of breast cancer cells. Taken together, HSD11 β 1 would be a novel target for suppressing breast cancer metastasis.

Adrenosterone is an FDA-approved drug and currently used as a daily supplement for bodybuilders. Financial toxicity in cancer treatment is increasingly recognized as a serious concern for cancer patients²². Therefore, daily intake of Adrenosterone might reduce medicine costs for breast cancer treatment.

Primary tumors of Adrenosterone-treated mice were slightly smaller than that of vehicle-treated mice but proliferative and apoptotic indexes in these tumors were same. (Extended Data Fig. 5a-c). Previous study also shows Adrenosterone does not affect primary tumor growth¹⁷. Furthermore, even 50 μ M Adrenosterone treatment hardly affected viability

of MDA-MB-231 cells in vitro (Extended Data Fig. 10). Therefore, we conclude that Adrenosterone suppresses breast cancer metastasis without affecting primary tumor growth.

11-KP and 11-OHP are reported to exist in the serum but we failed to detect endogenous 11-KP and 11-OHP in HSD11 β 1-expressing breast cancer cells²³. We only detected 11-OHP when HSD11 β 1-expressing breast cancer cells were cultured in presence of 10nM 11-KP (Fig. 4a). 11-KP and 11-OHP might be rapidly catalyzed into downstream metabolites and that results in the non-detection of them. Further studies are needed to investigate 11-OHP levels in the serum and breast tumors derived from patients with HSD11 β 1 positive breast cancer and uncover metabolic pathways which yield 11-KP and catalyze 11-OHP.

Recent study shows glucocorticoids and GR contribute to breast cancer metastasis¹¹. However, HSD11 β 1-expressing breast cancer cells failed to convert cortisone into cortisol and cortisol did not induce EMT in mammary epithelial cells. Furthermore, knockdown of GR did not affect HSD11 β 1-driven mesenchymal properties (Extended Data Fig. 6bc and 9d). Therefore, we conclude cortisol and GR would not be involved in the mechanism by which HSD11 β 1 promotes breast cancer metastasis.

The molecular mechanism of ectopic expression of HSD11 β 1 in breast cancer cells remain to be elucidated. Among the 14 human breast cancer cell lines investigated, three breast cancer cell lines: MCF10A, MDA-MB-468 and MDA-MB-159 cells express HSD11 β 1 mRNA but no HSD11 β 1 protein (Fig. 1a and Extended Data Fig. 1a). Therefore, the ectopic expression in breast cancer cells might involve at least a two step deregulation at transcriptional and post-transcriptional levels. CCAAT/ enhancer binding protein (C/EBP β) might contribute to the former since the promoter of HSD11 β 1 gene contains several binding sites for C/EBP β and elevated expression of C/EBP β mRNA is associated with breast cancer

metastasis^{24 25}. The mechanism of the latter is not reported yet and future studies are required.

Online Methods

Cell lines

MCF10A, MCF7, T47D, BT474, MDA-MB-468, BT453, MDA-MB-436, MDA-MB-157, Hs578T, BT549 and MDA-MB-231 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). HuMEC cells were obtained from Thermo Fisher (Waltham, MA). SUM-159PT cells were Asterand Bioscience (Detroit, MI). All culture methods followed the supplier's instructions.

Immunoblotting

Western blotting was performed as described previously²⁶. E-cadherin, EpCAM, N-cadherin, Vimentin, GR, Snail-1, GAPDH antibodies were obtained from Cell Signaling Technologies. A HSD11b1 antibody was obtained from Abcam. ki-67 and PPAR- α antibodies were obtained from Santa Cruz Biotechnology.

Plasmids

The fragment of human HSD11 β 1 was amplified from cDNA that was prepared from MDA-MB-231 cells. The amplified fragment was cloned into the pCDH-Hygro. pCDH-EF1-Luc2-T2A-tdTomato was obtained from Addgene.

shRNA mediated gene knockdown

The short hairpin RNA (shRNA)-expressing lentivirus vectors were

constructed using pLVX-shRNA1 vector (Clontech). HSD11 β - shRNA_#1–targeting sequence is GCTCCAAGGAAAGAAAGTGAT; HSD11 β -shRNA_#2–targeting sequence is CGAGCTATAATATGGACAGAT. PPAR- α - shRNA_#1–targeting sequence is AAGGCCTCAGGCTATCATTAC; PPAR- α - shRNA_#2–targeting sequence is GAGCATTGAACATCGAATGTA. LacZ-shRNA– targeting sequence is CTACACAAATCAGCGATT

Immunofluorescence

Immunofluorescence microscopy assay was performed by previously described (16). Goat anti-mouse and goat anti-rabbit immunoglobulin G (IgG) antibodies conjugated to Alexa Fluor 488 (Life Technologies) and diluted at 1:100 were used. Nuclei were visualized by the addition of 2 μ g/ml of 4', 6-diamidino-2-phenylindole (DAPI) and photographed at 100x magnification by a fluorescent microscope BZ-X700 (KEYENCE, Japan).

Boyden chamber assay

Boyden chamber assay was performed as described previously ¹⁷.

Mouse Xenograft experiments

Female NOD-*scid-Il2rg^{null}* (NSG) mice were obtained from Japan Charles River. Two days before MCF7 cell inoculation, Estrogen tablet (Innovative research of america) was inoculated into the back in the neck of NSG mice. Either MCF7 or MDA-MB-231 cells were injected into the 4th mammary fat pad of the mice. To monitor tumor growth and metastases, mice were imaged biweekly by IVIS Imaging System (ParkinElmer). All mice were handled according to the institutional guidelines established by the Animal Care Committee of the

National Cancer Center. The experimental protocols were approved by the Animal Ethics Committee of the National Cancer Center (approval number #T17502 and T17504).

Zebrafish Xenograft experiments

Tg(kdrl:eGFP) zebrafish was provided by Dr. Stainier (Max Planck Institute for Heart and Lung Research). Approximately 100–400 of red fluorescence protein (RFP)-labeled MCF7 cells were injected into the duct of Cuvier of the zebrafish at 2 dpf.

Statistics

Data were analyzed by Student's *t* test; $p < 0.05$ was considered significant.

Acknowledgments

We sincerely appreciate Prof. Stainier (Max Planck Institute for Heart and Lung Research) for providing *Tg(kdrl:eGFP)* zebrafish to us. This work was supported in part by research funds from the Yamagata prefectural government and the City of Tsuruoka.

Author contributions

Design research; J.N. Conducting experiments; J.N, T.I., T.N. and S.Y Analyzing data; J.N., T.I, T.N., S.Y., C.Y., G.N, T.O., T.S., S.F. Writing the paper; J.N. Funding Acquisition; H.M. Supervision; H.M.

Competing interests

J.N., T.I, T.N., S.Y., C.Y., G.N, T.O., T.S., S.F., and H.M. declare no conflict of interest.

Material and Correspondence

Joji Nakayama

Tsuruoka Metabolomics Laboratory, National Cancer Center

246-2, Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan 997-0052

E-mail: zmetastasis@gmail.com

References

- 1 Nguyen., D. X., Bos., P. D. & Massagué., J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer* **9**, 274-284 (2009).
- 2 Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis *Science* **331**, 1559-1564 (2011).
- 3 Welch, D. R. & Hurst, D. R. Defining the Hallmarks of Metastasis *Cancer research* **79**, 3011-3027. (2019).
- 4 Lu, W. & Kang, Y. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. *Developmental Cell* **49**, 361-374 (2019).
- 5 Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells *Nat Rev Cancer* **21**, 325-338 (2021).
- 6 Nieto, M. A., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. EMT: 2016 *Cell* **166**, 21-45 (2016).
- 7 Kröger, C. *et al.* Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells *Proc Natl Acad Sci U S A* **116**, 7353-7362 (2019).
- 8 Pastushenko, I. *et al.* Identification of the tumour transition states occurring during EMT *Nature* **556**, 463-468 (2018).
- 9 Nelson, E. R. *et al.* 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology. *Science* **342**, 1094-1098 (2013).
- 10 Finlay-Schultz, J. & Sartorius, C. A. Steroid Hormones, Steroid Receptors, and Breast Cancer Stem Cells. *J Mammary Gland Biol Neoplasia* **20**, 39-50 (2015).
- 11 Obradović, M. M. S. *et al.* Glucocorticoids promote breast cancer metastasis *Nature* **567**, 540-544. (2019).
- 12 Huang, B., Song, B.-L. & Xu, C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities *Nat Metab* **2**, 132-141 (2020).
- 13 Karen, C., Megan, H. & Jonathan, S. 11 β -hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. *Physiol Rev* **93**, 1139-1206 (2013).
- 14 Jakob, L., Günther, W. & Anthony, B., Miller. Plasma 7 β -hydroxycholesterol as a possible predictor of lung cancer risk *Cancer Epidemiol Biomarkers Prev* **11**, 1630-1637. (2002).
- 15 Adina, F., Turcu, & Richard, J., Auchus. Clinical significance of 11-oxygenated androgens. *Curr Opin Endocrinol Diabetes Obes* **24**, 252-259 (2017).
- 16 Lilia, A., Kristan, A. & Christopher, R., Mueller. Stress and breast cancer: from epidemiology to molecular biology. *Breast Cancer Res* **13**, 208 (2011).
- 17 Nakayama, J., Lu, J.-W., Makinoshima, H. & Gong, Z. A Novel Zebrafish Model of Metastasis Identifies the HSD11 β 1 Inhibitor Adrenosterone as a Suppressor of Epithelial-Mesenchymal Transition and Metastatic Dissemination. *Mol Cancer Res* **18**, 477-487. (2020).

- 18 Swart, A. C. *et al.* 11 β -hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5 α -reductase yielding 11 β -hydroxy-5 α -androstenedione *J Steroid Biochem Mol Biol* **138**, 132-142 (2013).
- 19 Sun, M. *et al.* Risk-association of CYP11A1 polymorphisms and breast cancer among Han Chinese women in Southern China. *Int J Mol Sci* **13**, 4896-4905 (2012).
- 20 Turcu, A. F., Rege, J., Auchus, R. J. & Rainey, W. E. 11-Oxygenated androgens in health and disease. *Nat Rev Endocrinol* **16**, 284-296 (2020).
- 21 Kristensen, V. N. & Borresen-Dale, A. L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism *Mutat Res* **462**, 323-333 (2000).
- 22 Jagsi, R. *et al.* Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer *Cancer* **124**, 3668-3676 (2018).
- 23 Toit, T. d., Finken, M. J. J., Hamer, H. M., Heijboer, A. C. & Swart, A. C. C11-oxy C 19 and C11-oxy C 21 steroids in neonates: UPC 2-MS/MS quantification of plasma 11 β -hydroxyandrostenedione, 11-ketotestosterone and 11-ketoprogesterone *Steroids* **135**, 1-5 (2018).
- 24 Cynthia, A., Zahnow. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases *Expert Rev Mol Med* **8**, e12 (2009).
- 25 Veer, L. J. v. t. *et al.* Gene expression profiling predicts clinical outcome of breast cancer (2002).
- 26 Nakayama, J. *et al.* BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. *Blood* **113**, 1483-1492 (2009).

Figure 1

Fig. 1_HSD11β1 expression in breast cancer is associated with poor prognosis.

a, Immunoblot analysis of HSD11β1, epithelial marker; E-cadherin and EpCAM and mesenchymal marker; N-cadherin and vimentin in immortalized epithelial cells (MCF10A), non-metastatic breast cancer cell lines (MCF7, BT474, MDA-MB-435) and metastatic breast cancer cell lines (MDA-MB-436, Hs578T, SUM159PT, BT549, MDA-MB-231); Histone H3 loading control is shown. **b**, Immunohistochemical staining for HSD11β1 and E-cadherin protein in specimens from either HER2-positive or triple-negative breast tumor. Magnification, x. **c**, The frequency of either HSD11β1-positive (red) or negative (black) in luminal A, luminal B, HER2-positive or triple-negative breast tumors. **d**, Overall survival of luminal A, luminal B, HER2-positive or triple-negative breast cancer patients with either HSD11β1-positive or negative. The survival distributions of these patients were calculated by a long-rank test and indicated in each graph.

Figure 2

Fig. 2_ HSD11β1 promotes EMT-mediated breast cancer metastasis

a, E-cadherin, EpCAM, Vimentin N-cadherin and Snail1 expressions in MCF10A, HuMEC and MCF7 cells through western blotting analysis; Histone H3 loading control is shown in the bottom. **b**, The morphologies (Top) of MCF7 cells expressing either control vector, HSD11β1 or HSD11β1 mutant were revealed by phase contrast microscopy.

Immunofluorescence staining (bottom) of E-cadherin (Red) and Vimentin (Green) in these cells. **c**, Effect of HSD11β1 on cell motility and invasion of these MCF7 cells. These MCF7

cells were subjected to Boyden chamber assays. 1% fetal bovine serum (FBS) (v/v) was used

as the chemoattractant in both assays. **d**, Representative images of metastatic burden of the mice that were inoculated with MCF7 cells expressing either control vector (Top) or HSD11 β 1 (bottom) on day 42 post injection taken using an IVIS Imaging System. **e**, Number of metastatic nodules in the lung (left) and liver (right) of the mice.

Figure 3

Fig. 3_ Pharmacological and genetic inhibition of HSD11β1 suppressed breast cancer metastasis

a. Protein expressions levels of E-cadherin and HSD11β1 in the primary tumors from the mice that were inoculated with MDA-MB-231 cells expressing shRNA targeting for either LacZ, HSD11β1_#1 or #2 are shown; Histone H3 is used as loading control for whole cell. **b,** Representative images of metastatic burden of the mice that were inoculated with MDA-MB-231 cells expressing shRNA targeting for either LacZ (Top), HSD11β1_#1 (middle) or #2 (bottom) on 12 weeks post injection taken using an IVIS Imaging System. **c,** Number of metastatic nodules in the lung of the mice. **d,** Representative images of metastatic burden of either vehicle (Top) or Adrenosterone-treated mice (bottom) at day 60 post injection taken

using an IVIS Imaging System. **e**, Number of metastatic nodules in the lung (left) and liver (right) of the mice.

Figure 4

Fig. 4_ HSD11β1 produced 11β-hydroxyprogesterone induced EMT

a, 11-OHP levels in MCF7 and HSD11 β 1 expressing breast cancer cells by mass spectrometer analyses. These cells were treated with either vehicle, 11-KP or 11-KP and Adrenosterone for six hours and then metabolites were collected and analyzed. **b**, E-cadherin, EpCAM, Vimentin N-cadherin and Snail1 expressions in either vehicle or 11-OHP-treated MCF10A cells. **c**, Effect of 11-OHP on cell motility and invasion of MCF10A cells. MCF10A cells were treated with Either vehicle or 11-OHP for 6 hours and then were subjected to Boyden chamber assays. 1% fetal bovine serum (FBS) (v/v) was used as the chemoattractant in both assays. **d**, Representative images of dissemination of vehicle or 11-OHP-treated MCF7 cells in zebrafish xenotransplantation model. The fish that were inoculated with MCF7 cells, were treated with either vehicle (top) or 11-OHP (lower). White arrows head indicate disseminated MCF7 cells. The images were shown in 4x magnification. Scale bar, 100 μ m. The mean frequencies of the fish showing head, trunk, or end-tail dissemination were counted (graph on bottom). Each value is indicated as the mean $\pm$ SEM of three independent experiments. Statistical analysis (Student's t test). **e**, E-cadherin, EpCAM, Vimentin and Snail1 expressions HSD11 β 1-overexpressing MCF7 cells which express shRNA targeting for either LacZ, PPAR- α _#1 or #2 are shown; Histone H3 is used as loading control for whole cell. **f**, E-cadherin, Vimentin and PPAR- α expressions in either vehicle or 11-OHP-treated MCF10A cells which express shRNA targeting for either LacZ, PPAR- α _#1 or #2 are shown; Histone H3 is used as loading control for whole cell. **g**, The morphologies (Top) of either vehicle or 11-OHP-treated MCF10A cells which express shRNA targeting for either LacZ, PPAR- α _#1 or #2, were revealed by phase contrast microscopy. Immunofluorescence staining (bottom) of E-cadherin (Red) and Vimentin (Green) in these cells.

Extended Data Fig. 1

a. HSD11β1 mRNA expression in immortalized epithelial cells (MCF10A), non-metastatic breast cancer cell lines (MCF7, BT474, MDA-MB-435) and metastatic breast cancer cell lines (MDA-MB-436, Hs578T, SUM159PT, BT549, MDA-MB-231). **b.** Overall survival of all sub-types of breast cancer patients with either HSD11β1-positive or negative. The survival distributions of these patients were calculated by a long-rank test and indicated in each graph.

Extended Data Fig. 2

a, E-cadherin, EpCAM, Vimentin N-cadherin and HSD11 β 1 expressions in MCF10A and HuMEC cells which were treated with either vehicle, TGF- β or StemVivo for five days through western blotting analysis; Histone H3 loading control is shown in the bottom. **b**, The morphologies of MCF10A and HuMEC cells which express either control vector or HSD11 β 1 revealed by phase contrast microscopy. **c**, Representative images of primary tumor

of the mice that were inoculated with MCF7 cells expressing either control vector (Top) or HSD11 β 1 (bottom) on day 21 post injection taken using an IVIS Imaging System. **d**, Mean volumes (n=10 per group) of primary tumors formed in the mammary fat pad of the mice inoculated with MCF7 cells expressing either vector control or HSD11 β 1 at 3 weeks post injection. **e**, ki67 expression level in primary tumors formed in the mammary fat pad of the mice inoculated with MCF7 cells expressing either vector control or HSD11 β 1 at 4 weeks post injection; Luciferase loading control is shown in the bottom

Extended Data Fig. 3

a, Representative images of metastatic tumor in the lung, liver, lymph node and spleen of the mice that were inoculated with MCF7 cells expressing either control vector (left) or HSD11 β 1 (right) on 6 weeks post injection taken using an IVIS Imaging System. **b**, Representative images of metastatic tumor in the lymph node and spleen of the mice that were inoculated with MCF7 cells expressing either control vector (left) or HSD11 β 1 (right) on 6 weeks post injection taken using an IVIS Imaging System.

Extended Data Fig. 4

a. Protein expressions levels of E-cadherin and HSD11 β 1 in the primary tumors from the mice that were inoculated with either Sum159PT or Hs578T cells expressing shRNA targeting for either LacZ, HSD11 β 1_#1 or #2 are shown; Histone H3 is used as loading control for whole cell. **b,** Representative images of metastatic tumor in the lung and liver of the mice that were inoculated with MDA-MB-231 cells expressing shRNA targeting either LacZ (left), HSD11 β 1_#1 (middle) or #2 (right) on 12 weeks post injection taken using an IVIS Imaging System. **c,** Representative H&E staining of the lung from the mice that were inoculated with MDA-MB-231 cells expressing shRNA targeting either LacZ (left) or HSD11 β 1 (right). **d,** Protein expressions levels of HSD11 β 1 in the primary tumors from the

mice that were inoculated with MDA-MB-231 cells expressing shRNA targeting for either LacZ, HSD11 β 1_#1 or #2 are shown; Luciferase loading control is shown in the bottom.

Extended Data Fig. 5

a, Representative images of MDA-MB-231 primary tumors formed in the mammary fat pad of either vehicle or Adrenosterone-treated mice on 4 weeks post injection taken using an IVIS Imaging System. **b**, Mean volumes (n=10 per group) of primary tumors formed in the

mammary fat pad of the mice treated with either vehicle or Adrenosterone. **c**, Ki-67 and cleaved caspase 3 levels in the primary tumors from the mice treated with either vehicle or Adrenosterone at 4 weeks post injection; Luciferase loading control is shown in the bottom. **d**, Representative images of metastatic tumor in the lung and liver of the mice treated with either vehicle or Adrenosterone on 12 weeks post injection taken using an IVIS Imaging System.

Extended Data Fig. 6

a, Cortisol levels in MCF10A, HuMEC, and HSD11 β expressing breast cancer cells by ELISA (Top) and mass spectrometer analyses (bottom). Culture media of MCF10A, HuMEC and Sum-159PT cells contains hydrocortisone. **b**, E-cadherin expression in cortisol-treated MCF10A (Top) and HuMEC (bottom). TGF- β -treated MCF10A cells which underwent EMT were used as positive control; GAPDH and Histone H3 loading control are shown in the

bottom. **c**, Cortisol levels in MCF10A, HuMEC, and HSD11 β 1 expressing breast cancer cells by mass spectrometer analyses. These cells were treated with either vehicle, cortisone or cortisone and Adrenosterone for six hours and then metabolites were collected and analyzed.

Extended Data Fig. 7

a, 11-OHA4 levels in MCF10A, HuMEC and HSD11 β 1 expressing breast cancer cells by mass spectrometer analyses (bottom). These cells were treated with either vehicle or Adrenosterone for six hours and then metabolites were collected and analyzed. **b**, 11-OHT levels in MCF10A, HuMEC, and HSD11 β 1 expressing breast cancer cells by mass spectrometer analyses. These cells were treated with either vehicle, 11-KT or 11-KT and Adrenosterone for six hours and then metabolites were collected and analyzed. **c**, Immunoblot analysis of CYP11A1, HSD3 β 1, CYP17A1 and CYP21A2 in immortalized epithelial cells (MCF10A), non-metastatic breast cancer cell lines (MCF7, BT474, MDA-MB-435), metastatic breast cancer cell lines (MDA-MB-436, Hs578T, SUM159PT, BT549, MDA-MB-231) and HSD11 β 1-overexpressing MCF7 cells (#2-7 and #2-19); GAPDH loading control is shown.

Extended Data Fig. 8

a, 11-OHP levels in MCF10A, HuMEC, and HSD11 β 1 expressing breast cancer cells by mass spectrometer analyses. These cells were treated with either vehicle, 11-KP or 11-KP and Adrenosterone for six hours and then metabolites were collected and analyzed. **b**, 21-Deoxycortisol levels in MCF10A, HuMEC, and HSD11 β 1-expressing breast cancer cells by mass spectrometer analyses. These cells were treated with either vehicle, 21-DF or 21-DF and Adrenosterone for six hours and then metabolites were collected and analyzed.

Extended Data Fig. 9

a, E-cadherin, EpCAM, Vimentin N-cadherin and Snail1 expressions in either vehicle, 11-OHT or 21-Deoxycortisol-treated MCF10A cells. **b**, Effect of either 11-OHT or 21-Deoxycortisol on cell motility and invasion of MCF10A cells. MCF10A cells were treated with either 11-OHT or 21-Deoxycortisol for five days and subjected to Boyden chamber assays. 1% fetal bovine serum (FBS) (v/v) was used as the chemoattractant in both assays. **c**, E-cadherin, Vimentin N-cadherin, HSD11 β 1 and PPAR- α expressions in MCF10A cells which were transduced with either vehicle or HSD11 β 1 through western blotting analysis; Histone H3 loading control is shown in the bottom. **d**, E-cadherin, EpCAM, Vimentin, N-cadherin, HSD11 β 1 and GR in MCF7, VC, #2-7 and #2-19 cells which express shRNA

targeting for either LacZ, GR_#2 or #4 are shown; GAPDH is used as loading control for whole cell.

Extended Data Fig. 10

Cell viability of MDA-MB-231 cells cultured in the medium containing either vehicle or 50µm Adrenosterone was measured by an MTT assay over three days.